Literature DB >> 12759533

Clinicopathological significance of Nup88 expression in patients with colorectal cancer.

Anna Emterling1, Johanna Skoglund, Gunnar Arbman, Jose Schneider, Sofia Evertsson, John Carstensen, Hong Zhang, Xiao-Feng Sun.   

Abstract

OBJECTIVE: The nucleoporin Nup88 is overexpressed in a series of human malignancies, however, its clinicopathological significance has not been studied. Our aims were to analyze Nup88 expression in normal mucosa, primary tumors and metastases from colorectal cancer patients and further to identify relationships of Nup88 expression with clinicopathological and other factors.
MATERIALS AND METHODS: Using immunohistochemistry, we investigated Nup88 expression in 198 primary colorectal tumors, 96 normal mucosa samples and 35 lymph node metastases.
RESULTS: The results showed that the intensity of Nup88 expression increased from the normal mucosa to the primary tumors (p < 0.0001) and tended to increase from the primary tumors to the metastases (p = 0.15). Both primary tumors and metastases presented stronger expression in the invasive margin and vascular-invaded areas. Nup88 expression was positively related to distal tumor location (p = 0.01), infiltrative growth pattern (p = 0.04) and higher proliferative activity (p = 0.04) and reversely to the grade of differentiation (p = 0.02) and apoptosis (p = 0.049). Strong expression of Nup88 predicted a worse outcome in the patients with distal tumors during the follow-up period of up to 3 years (p = 0.02).
CONCLUSIONS: It seems that overexpression of Nup88 was involved in the tumorigenesis and aggressiveness of colorectal cancers, and Nup88 may be used as a prognostic factor in patients with distal tumors. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759533     DOI: 10.1159/000070294

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  12 in total

Review 1.  Nuclear mechanics in cancer.

Authors:  Celine Denais; Jan Lammerding
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

2.  Increased serum level of Nup88 protein is associated with the development of colorectal cancer.

Authors:  Zeng-Ren Zhao; Li-Jing Zhang; Yuan-Yuan Wang; Fang Li; Ming-Wei Wang; Xiao-Feng Sun
Journal:  Med Oncol       Date:  2011-08-24       Impact factor: 3.064

3.  Nucleoporin 88 expression in hepatitis B and C virus-related liver diseases.

Authors:  Martina Knoess; Anna Kordelia Kurz; Olga Goreva; Nuran Bektas; Kai Breuhahn; Magarethe Odenthal; Peter Schirmacher; Hans Peter Dienes; C Thomas Bock; Hanswalter Zentgraf; Axel zur Hausen
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

Review 4.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

5.  Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy.

Authors:  Ryan M Naylor; Karthik B Jeganathan; Xiuqi Cao; Jan M van Deursen
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 6.  The nuclear envelope environment and its cancer connections.

Authors:  Kin-Hoe Chow; Rachel E Factor; Katharine S Ullman
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

Review 7.  Oncogenic potential of nucleoporins in non-hematological cancers: recent update beyond chromosome translocation and gene fusion.

Authors:  Adhiraj Roy; Gopeshwar Narayan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-25       Impact factor: 4.553

8.  Nesprin-1 role in DNA damage response.

Authors:  Ilknur Sur; Sascha Neumann; Angelika A Noegel
Journal:  Nucleus       Date:  2014-04-29       Impact factor: 4.197

Review 9.  Multiple Export Mechanisms for mRNAs.

Authors:  Mildred Delaleau; Katherine L B Borden
Journal:  Cells       Date:  2015-08-28       Impact factor: 6.600

10.  The role of vimentin in the tumor marker Nup88-dependent multinucleated phenotype.

Authors:  Masaki Makise; Hideaki Nakamura; Akihiko Kuniyasu
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.